Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02471352
Other study ID # 150144
Secondary ID 15-AR-0144
Status Recruiting
Phase
First received
Last updated
Start date June 19, 2015
Est. completion date January 31, 2027

Study information

Verified date June 7, 2024
Source National Institutes of Health Clinical Center (CC)
Contact Monica Taylor, R.N.
Phone (301) 451-2221
Email monica.taylor@nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: - Skin disease can have many causes. It can have widespread consequences, and in rare cases can lead to death. Researchers want to determine the causes of various types of skin diseases and find a way to treat them. Objectives: - To determine the causes of various skin diseases and find ways to treat them. Eligibility: - People ages 2 and older who have: - A skin disease or at risk of developing a skin disease OR - A family member of persons with a skin disease - Healthy volunteers ages 2 and older Design: - Participants will be screened under a separate protocol. - Participants may take a survey about how their skin condition affects their quality of life. - Participants will have a medical history and a physical exam including a detailed skin exam. Pictures will be taken of their skin to document any skin disease. - Participants will have specimens collected. This may include: - Several teaspoons of blood taken at each visit - Stool samples - Nail and body fluid (like saliva) samples - Cheek swabs. The inside of the cheek will be scraped for about a minute in each direction to collect cells. - Collection of skin samples with: - A swab (like a Q-tip) - Gently scraping skin to remove the outer layers of cells - Applying and removing 1-inch pieces of tape - Participants may have up to 4 skin biopsies in 12 months, with 4 separate biopsies taken each time. - An area of skin will be numbed with an injection. - A piece of skin the size of a pencil eraser will be removed using a small instrument. - A flat scar usually develops at the biopsy site.


Description:

Background: - Skin diseases represent one of the most common medical problems in the United States, affecting 1 in 3 people at any given time. - Complex interactions between genetic background and the environment are relevant to understanding skin disease. - By studying dermatoses, we may gain insight into the complex host-environment interactions that give rise to or exacerbate these skin conditions, and into links between inflammation and cancer. Objective: -To procure biologic samples for exploratory cellular, molecular, genetic and genomic biological studies from subjects with dermatologic conditions, subjects at risk for developing dermatologic conditions and healthy volunteers in the support of NIH biomedical studies Eligibility: -Subjects with or at risk of developing dermatologic diseases, family members of subjects with dermatologic diseases, or healthy volunteers, including adults and children. Design: - The purpose of this study is to examine, in an exploratory fashion, a variety of biologic assays relevant to the investigation of dermatologic diseases. - Approximately 50 subjects are anticipated to consent to the study each year with an accrual ceiling of 500 consented subjects planned over 10 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 700
Est. completion date January 31, 2027
Est. primary completion date January 31, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Day to 100 Years
Eligibility - INCLUSION CRITERIA: - Eligible participants must: - Have a dermatologic condition, as determined by the PI or AIs, OR be at risk for developing a dermatologic condition, as determined by the PI or AIs, OR be a family member of a person with a dermatologic condition OR be a healthy volunteer, as defined as a person with no known significant health problems. - Be willing to provide biospecimens for research and clinical studies, and for storage to be used for future research. - Subjects of age greater than or equal to 2 years old are eligible. EXCLUSION CRITERIA: - Presence of conditions that, in the judgment of the investigator, may put the subject at undue risk or make them unsuitable for participation in the study. - Inability to comply with the requirements of the protocol.

Study Design


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procure biologic samples for exploratory cellular, molecular, genetic and genomic biological studies Collection of biologic samples Time of collection
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1